2 Sides of Celgene Corporation (CELG)’s Apremilast Results

Foolish take
I didn’t see anything with the phase 3 study that should impede the prospects for apremilast gaining approval. The lower efficacy could have some impact on sales, but the advantages of the drug — safety, convenience, and price — are still intact. My view is that apremilast should still be a blockbuster for Celgene, although sales will likely be on the lower end of the company’s forecasts.

My overall outlook on the company remains very positive. Apremilast is just one of several drugs that should contribute to Celgene’s growth over the next several years. There will always be good news and bad news with any drug company, but the best news for investors will be found in companies like Celgene that have the product depth to roll with the punches.

The article 2 Sides of Celgene’s Apremilast Results originally appeared on Fool.com.

Fool contributor Keith Speights has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.